leuprolide mesylate

Details

Files
Generic Name:
leuprolide mesylate
Project Status:
Active
Therapeutic Area:
Prostate cancer
Manufacturer:
Accord Healthcare Inc.
Call for patient/clinician input open:
Brand Name:
Camcevi
Project Line:
Reimbursement Review
Project Number:
PC0370-000
Call for patient/clinician input closed:
Tumour Type:
Genitourinary
Biosimilar:
No
Manufacturer Requested Reimbursement Criteria1:
Camcevi (leuprolide mesylate) is indicated for the treatment of adult patients with advanced prostate cancer.
Submission Type:
Initial
Fee Schedule:
Schedule C
Indications:
​​Camcevi (leuprolide mesylate) is indicated for the treatment of adult patients with advanced prostate cancer.
  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of Canada's Drug Agency. Reimbursement criteria from Canada's Drug Agency will be documented in the final recommendation, if applicable.
Key Milestones2
Call for patient/clinician input open11-Oct-24
Call for patient/clinician input closed06-Dec-24
Submission received22-Nov-24
Submission accepted06-Dec-24
Review initiated09-Dec-24
Draft CADTH review report(s) provided to sponsor for comment18-Mar-25
Deadline for sponsors comments27-Mar-25
CADTH review report(s) and responses to comments provided to sponsor02-May-25
Expert committee meeting (initial)14-May-25
Draft recommendation issued to sponsorMay 27, 2025
To
May 29, 2025
Draft recommendation posted for stakeholder feedback05-Jun-25
End of feedback period19-Jun-25